Cui Zhao1, Jian Liu2, Yifei Liu3, Jianguo Zhang4, Haomiao Zhou1, Xin Qian1, Hui Sun5, Xuewen Chen6, Miaosen Zheng1, Tingting Bian5, Lei Liu5. 1. Nantong University, Nantong, 226001, China. 2. Department of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, 226001, China. 3. Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 226001, China. ntdxliuyifei@sina.com. 4. Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 226001, China. 13815212431@163.com. 5. Department of Pathology, Affiliated Hospital of Nantong University, Nantong, 226001, China. 6. Department of Orthopedics, Second People's Hospital of Jingmen, Jingmen, 448000, China.
Abstract
BACKGROUND: Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature. METHODS: Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis. RESULTS: This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P < 0.001). Increased NEIL3 expression was related to advanced stage, larger tumor size and poor overall survival (p < 0.001) in three LUAD cohorts. The proportions of natural T regulatory cells and induced T regulatory cells increased in the high NEIL3 group, whereas those of B cells, Th17 cells and dendritic cells decreased. Gene set enrichment analysis indicated that NEIL3 may activate cell cycle progression and P53 signaling pathway, leading to poor outcomes. We identified nine prognosis-associated hub genes among 370 genes co-expressed with NEIL3. A 10-gene prognostic signature including NEIL3 and nine key co-expressed genes was constructed. Higher risk-score was correlated with more advanced stage, larger tumor size and worse outcome (p < 0.05). Finally, the signature was verified in test cohort (GSE50081) with superior diagnostic accuracy. CONCLUSIONS: This study suggested that NEIL3 has the potential to be an immune-related therapeutic target and an independent predictor of LUAD prognosis. We also developed a prognostic signature for LUAD with a precise diagnostic accuracy.
BACKGROUND:Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death. This study aimed to develop and validate reliable prognostic biomarkers and signature. METHODS: Differentially expressed genes were identified based on three Gene Expression Omnibus (GEO) datasets. Based on 1052 samples' data from our cohort, GEO and The Cancer Genome Atlas, we explored the relationship of clinicopathological features and NEIL3 expression to determine clinical effect of NEIL3 in LUAD. Western blotting (22 pairs of tumor and normal tissues), Real-time quantitative PCR (19 pairs of tumor and normal tissues), and immunohistochemical analyses (406-tumor tissues subjected to microarray) were conducted. TIMER and ImmuCellAI analyzed relationship between NEIL3 expression and the abundance of tumor-infiltrating immune cells in LUAD. The co-expressed-gene prognostic signature was established based on the Cox regression analysis. RESULTS: This study identified 502 common differentially expressed genes and confirmed that NEIL3 was significantly overexpressed in LUAD samples (P < 0.001). Increased NEIL3 expression was related to advanced stage, larger tumor size and poor overall survival (p < 0.001) in three LUAD cohorts. The proportions of natural T regulatory cells and induced T regulatory cells increased in the high NEIL3 group, whereas those of B cells, Th17 cells and dendritic cells decreased. Gene set enrichment analysis indicated that NEIL3 may activate cell cycle progression and P53 signaling pathway, leading to poor outcomes. We identified nine prognosis-associated hub genes among 370 genes co-expressed with NEIL3. A 10-gene prognostic signature including NEIL3 and nine key co-expressed genes was constructed. Higher risk-score was correlated with more advanced stage, larger tumor size and worse outcome (p < 0.05). Finally, the signature was verified in test cohort (GSE50081) with superior diagnostic accuracy. CONCLUSIONS: This study suggested that NEIL3 has the potential to be an immune-related therapeutic target and an independent predictor of LUAD prognosis. We also developed a prognostic signature for LUAD with a precise diagnostic accuracy.
Authors: Michel J Massaad; Jia Zhou; Daisuke Tsuchimoto; Janet Chou; Haifa Jabara; Erin Janssen; Salomé Glauzy; Brennan G Olson; Henner Morbach; Toshiro K Ohsumi; Klaus Schmitz; Markianos Kyriacos; Jennifer Kane; Kumiko Torisu; Yusaku Nakabeppu; Luigi D Notarangelo; Eliane Chouery; Andre Megarbane; Peter B Kang; Eman Al-Idrissi; Hasan Aldhekri; Eric Meffre; Masayuki Mizui; George C Tsokos; John P Manis; Waleed Al-Herz; Susan S Wallace; Raif S Geha Journal: J Clin Invest Date: 2016-10-17 Impact factor: 14.808
Authors: Jia Zhou; Jany Chan; Marie Lambelé; Timur Yusufzai; Jason Stumpff; Patricia L Opresko; Markus Thali; Susan S Wallace Journal: Cell Rep Date: 2017-08-29 Impact factor: 9.423
Authors: Silje Z Krokeide; Jon K Laerdahl; Medya Salah; Luisa Luna; F Henning Cederkvist; Aaron M Fleming; Cynthia J Burrows; Bjørn Dalhus; Magnar Bjørås Journal: DNA Repair (Amst) Date: 2013-06-05
Authors: Rafael Nuñez; Maria Jose Rodriguez; James Richard Perkins; Cristobalina Mayorga; Francisca Palomares; Francisca Gomez; Fernando M Jabato; Jose Cordoba-Caballero; Pedro Seoane; Jorge Losada; Javier Rojo; Maria Jose Torres Journal: Sci Rep Date: 2022-02-18 Impact factor: 4.379